Exon 11 Skipping of E-Cadherin RNA Downregulates Its Expression in Head and Neck Cancer Cells

Sanjai Sharma1, Wei Liao1, Xiaofeng Zhou2, David T.W. Wong3, and Alan Lichtenstein1

Abstract

E-cadherin is an important tumor suppressor gene whose expression is lost when cells acquire a metastatic phenotype. We analyzed the role of E-cadherin missplicing as a mechanism of its downregulation by analyzing a misspliced E-cadherin transcript that lacks exon 11 of this gene. This results in a frameshift and a premature termination codon that targets this transcript for degradation. Tumor tissues, including breast (20%, n = 9), prostate (30%, n = 9) and head and neck (75%, n = 8) cancer, express the exon 11-skipped transcripts (vs. nonmalignant controls) and its levels inversely correlate with E-cadherin expression. This is a novel mechanism of E-cadherin downregulation by missplicing in tumor cells, which is observed in highly prevalent human tumors. In the head and neck cancer model, nontumorigenic keratinocytes express exon 11-skipped splice product two- to sixfold lower than the head and neck tumor cell lines. Mechanistic studies reveal that SFRS2 (SC35), a splicing factor, as one of the regulators that increases missplicing and downregulates E-cadherin expression. Furthermore, this splicing factor was found to be overexpressed in 5 of 7 head and neck cell lines and primary head and neck tumors. Also, methylation of E-cadherin gene acts as a regulator of this aberrant splicing process. In 2 head and neck cell lines, wild-type transcript expression increased 16- to 25-folds, whereas the percentage of exon 11-skipped transcripts in both the cell lines decreased five- to 30-folds when cells were treated with a hypomethylating agent, azacytidine. Our findings reveal that promoter methylation and an upregulated splicing factor (SFRS2) are involved in the E-cadherin missplicing in tumors. Mol Cancer Ther; 10(9); 1751–9. ©2011 AACR.

Introduction

Presence of a premature termination (PTC) codon mutation results in an in-frame stop codon in RNA. These RNA transcripts are degraded by pathway called the nonsense-mediated decay (NMD) pathway that is active in all mammalian cells (1–3). Theoretically, the NMD prevents expression of truncated proteins that could act as dominant negatives and have adverse effects. PTC in a RNA transcript could be because of a point mutation or a frameshift, and the rapid degradation of PTC-containing RNAs can be a mechanism by which loss-of-function of potential tumor suppressor genes can occur. Alternative splicing affects more than 60% of the human genes (4) and cancer cells are known to have different splicing patterns as compared with their normal counterparts (5). Cancer cells are also associated with alternative splicing of several tumor suppressors genes, such as BRCA1/2, APC, WT1, mdm2, and ATM (6–10) with subsequent NMD-mediated degradation and loss of expression.

Changes in splicing patterns in tumor cells could be secondary to aberrant expression of splice factors affecting the splicing patterns of a number of genes. Recent reports on aberrant expression of serine-arginine rich (SR) proteins, SFRS1 and SFRS2 splicing factors exemplify their potential role in transformation (11, 12). Splicing factors are also regulated by oncogenic signaling pathways that affect activity of SR proteins (13).

Methylation affects transcription of the gene (14) that in turn is intricately linked to splicing as both processes occur simultaneously (15, 16). As splicing factors are also known to associate with the transcriptional machinery (17), the nature of the transcriptional complex assembled for the transcription of a particular gene influences the splicing factors available for splicing which in turn affects the splicing patterns. Methylation changes can also occur at the lysine residues of the histones that are able to modify the chromatin structure, which are now recognized as important regulator of alternative splicing (18, 19), and in fact, define the exon—intron boundaries (20). The epigenetic events associated with methylation...
could thereby potentially affect splicing with change in transcriptional rates and histone modifications.

We have previously reported an E-cadherin exon 11–skipped, alternatively spliced transcript that is subject to NMD degradation in chronic lymphocytic leukemia cells (21). This tumor suppressor gene has a critical role in maintaining cell–cell adhesion and cell–matrix interactions (reviewed in refs. 22, 23). As these functions are important for the epithelial membrane integrity, mis-splicing of this transcript was analyzed in epithelial cancers. We report the presence of this exon 11–skipped transcript in primary human cancer tissues and further characterize its regulation by splicing factors and methylation status of the E-cadherin gene.

Materials and Methods

Primary human tissues and TissueScan arrays

Primary human head and neck cancer specimens (8 matched pairs) and matched normal controls were obtained from the Cooperative Human Tissue Network. Tissue RNA was isolated by grinding frozen tissues in RLT buffer (Qiagen RNA Kit) followed by the kit isolation protocol. TissueScan quantitative PCR arrays for breast, prostate, and other cancers were purchased from Origene. Each tissue type has 9 individual tumor cDNA and 3 tissue-matched normals. Both primary human tissues and TissueScan arrays were analyzed by light microscopy to confirm the quality and the nature of the tissues.

Transcript-specific real-time PCR

E-cadherin expression in cells was analyzed by a real-time PCR. The 5′-primer GATGTGCTGGATGTGAATG localizes to exon 10 of the E-cadherin gene. The 3′-primer CACATCACAGATCGACAGGAGAA localizes to the exon 12. The TaqMan probe 10–11 (TAAACATCGGATTTGAGAGAC) determining the wild-type E-cadherin transcript level binds to the junction of exon 10–exon 11. The expression level of the skipped or aberrant transcript (transcript lacking exon 11) is determined by the same set of PCR primers as mentioned above with a TaqMan probe 10–12 (CAGAAATACAGTCTCCAGTTG) binding to the exon 10–exon 12 junction. Real-time PCR for actin expression was used as a control and relative expression of transcripts was determined by comparative C\textsubscript{i} method of Pfaff (24) that compares transcript levels in different samples by using a coamplified internal control.

Cell culture and microarray analysis

The head and neck cancer cell lines UMSCC1, 2, 12, 14, and 22b were obtained from University of Michigan, Ann Arbor, MI. Cal27 was obtained from American Type Culture Collection. Telomerase reverse transcriptase immortalized keratinocytes (tert-kert) and normal human oral keratinocytes (NHOX) cells were obtained from Dr. David Wong’s lab (UCLA Dental School) and cultured as previously described (25). No further authentication of the cell lines was done by the authors. Emetine treatment was done at concentration of 100 μg/mL for 8 hours (10). In some groups, actinomycin D was added at a concentration of 2 μg/mL, together with emetine (100 μg/mL; ref. 26). For microarray analysis, cRNA was obtained as per standard protocols and hybridized to the Affymetrix chip 133A (Affymetrix). The nonsense transcript enrichment index (26) score is the ratio of upregulation of the signal intensity on emetine treatment of head and neck squamous cell carcinomas cells of a particular probe set divided by the ratio of upregulation of signal intensity of nonmalignant tert-kert cells for the same probe set.

Minigene constructs

Exon 10, 11, and 15 of the E-cadherin gene along with their flanking intronic regions were cloned into a minigene construct pDup (gift from Dr. Douglas Black, UCLA; ref. 27). The exon 10 is 245 base pairs (bp) and a DNA fragment from position −325 from 5′-exon–intron junction to +338 from the 3′-exon–intron junction was amplified by PCR from normal human peripheral blood mononuclear cells DNA and cloned in the pDup vector at the Apa1 and BglII site. Similarly, for exon 11 (146 bp) a fragment −623 to +544 and for exon 15, a fragment from −477 to +518 was cloned. The constructs were transiently transfected in SCC12 cells and cells were analyzed by reverse transcription PCR (RT-PCR) analysis. The primers for amplification are GACACCATGACATGCACC and GCAGCTCAGTCAGTGCCA, which bind to β-globin exon E1 and E3, respectively. To quantify the amount of correctly or aberrantly spliced transcripts, a real-time PCR was conducted with TaqMan probes specifically binding the junction of β-globin E1–exon 11 or β-globin E1–β-globin E3. Cells were transfected with 1 μg of plasmid along with 5 μg of bluescript DNA and Lipofectamine 2000 (Invitrogen). Forty-eight hours after transfection, cells were analyzed by real-time RT-PCR.

Analysis of splicing factors and short interfering RNA knockdown

Head and neck cell lines were analyzed for expression of splicing factors SFRS1, 2, 5, and 6 with real-time PCR (Applied Biosystems). The SCC12 and SCC1 lines were transfected with 10 nmol/L short interfering RNA (siRNA) and 1 μg of the minigene exon 11 construct RNA against SFRS2 (Santa Cruz Biotechnology). Western blot analysis for SFRS2 expression was carried out with Santa Cruz Biotechnology antibody, E-16. Forty-eight hours after transfection, the cells were analyzed for SFRS2 expression and quantitative transcript–specific real-time PCR analysis for E-cadherin splicing.

DNA hypomethylation

SCC1 and 22b cell lines were treated with 5-aza-deoxycytidine (5 μmol/L) for 96 hours and cells analyzed for E-cadherin RNA expression by transcript-specific real-time PCR. In parallel, DNA was isolated and bisulfite-modified methylation-specific PCR conducted as described (28), along with Western blot analysis for E-cadherin.
Results

Wild-type and exon 11–skipped transcript
To ascertain whether exon 11–skipped transcripts are present in solid tumors, we screened 8 pairs of head and neck cancer primary tissues (tumor and matched normal). For lymphomas, melanomas, sarcomas, breast, kidney, liver, pancreas prostate cancers, a tissue scan PCR array with 9 tumor cDNAs and 3 normal tissue cDNAs was analyzed. A transcript-specific real-time PCR was conducted on all tissues that distinguished normal wild-type transcripts from the exon 11–skipped transcripts (Fig. 1A).

Figure 1B shows percent of each tumor type with E-cadherin RNA expression, which is decreased, compared with corresponding control tissue (at least 50% expression decrease vs. nonmalignant control tissue, black bars). To estimate the relative abundance of the aberrant transcript as compared with the wild type in tissues, the difference between the ΔCt of the transcript-specific PCR reactions was calculated by using the cycle difference in the 2 transcripts to calculate the relative abundance, for example, with 8 cycle difference between the 2 transcripts, the exon 11–skipped transcript is 0.4% of the wild type. The percent of each tumor type with at least a 2-fold higher level of exon 11–skipped transcript compared with corresponding normal tissue is shown in Fig. 1B (open bars). As shown in Fig. 1B, tumor types with the highest incidence of loss of normal E-cadherin RNA expression were kidney cancer (90%), liver cancer (100%), lymphoma (80%), and head and neck cancer (75%). Although the sample size in this screening is relatively small, these data are consistent with previous literature (29–31) that also identified loss of E-cadherin expression as being frequent in these cancers. Of these 4 tumor types, the one with the highest frequency of increased expression of exon 11–skipped transcripts was head and neck cancer (open bar, 7 of 9 specimens), and this tumor was chosen for further analysis.

Figure 1C depicts the results of the transcript-specific PCR assay for each head and neck cancer specimen. Relative amounts of wild-type RNA are shown in closed bars and percentage of exon 11–skipped transcripts in open bars (log scale). As can be seen, there is an inverse correlation between the relative amount of normal E-cadherin RNA expression and exon 11–skipped RNA (P = 0.08, correlative coefficient). It should be noted that this is an underestimation of the exon 11–skipped transcripts as the NMD pathway had been active in these cells, which would have caused constant rapid degradation of this transcript and not the wild type.

Microarray analysis with inhibition of NMD pathway
An unbiased screen for PTC codons in 5 head and neck cancer cell lines (UMSCC1, 2, 12, 14, and 22b) also supported the frequency of a PTC-bearing transcript that was caused by exon 11 skipping. In this screen, the NMD pathway was paralyzed by a short exposure to emetine as previously described (26) and microarray RNA profiling was done with or without NMD paralysis. Immortalized nontransformed tert-kert cells were used as control cell and compared with 5 head and neck cell lines (GEO accession number GSE29788). A more than 5-fold mean emetine-induced upregulation was observed in 199 of 23,000 probes. The initial hits (significant upregulations by emetine) were also analyzed...
for RNA signal intensity versus tert keratinocytes in the absence of emetine. Our reasoning was that those with downregulated expression were most likely to represent loss-of-function tumor suppressors. The E-cadherin gene was identified as one of the top 100 maximally downregulated genes when comparing head and neck tumor lines to tert keratinocytes, and its RNA signal was significantly increased upon NMD paralysis with emetine (Supplementary Data).

To confirm these findings, we treated the head and neck line UMSCC14A with emetine to paralyze the NMD. As emetine exposure also results in upregulation of a number of stress response genes via stress-induced transcription, actinomycin D was added to block the upregulation of stress-induced transcription (32). Following exposure to emetine or emetine + actinomycin D, RT-PCR analysis was done (Fig. 2A). The primers for this PCR bind to the 3' end of the E-cadherin gene, and a stronger band was observed in the emetine-treated cells. Importantly, addition of actinomycin D did not prevent this upregulation, indicating the emetine-induced upregulation was not due to a stress response that activates transcription. Figure 2A shows a contrasting example of the fibroblast growth factor receptor substrate 2 (FRS2) gene for which the emetine-induced upregulation was prevented by addition of actinomycin D. Upon sequencing the entire cDNA of FRS2, no PTC mutations were identified. In contrast, sequencing showed that, in addition to the wild-type E-cadherin transcript, a smaller transcript was identified that lacked exon 11 and resulted in a frameshift and a PTC located in exon 12 as previously described (21).

**Half-life of the exon 11–skipped transcript**

To further support the notion that the PTC-containing RNA is rapidly degraded by the NMD, we studied the
and sequenced from UMSCC12 and UMSCC22b cells, Minigene constructs increased in malignant head and neck epithelial tissues. nontransformed oral epithelial cells but is markedly cells. Thus, exon 11 skipping occurs at a low level in fold higher in all the head and neck cell lines than tert-kert cells treated with emetine (Fig. 2F), in which the ment was done on the head and neck cancer cell lines and head and neck cancer cell lines; Fig. 2E). A similar experi-

tory observed in malignant tissue, exon 11 along with its intronic regions were cloned into the pDup minigene construct (27). As controls, we also cloned E-cadherin exon 10 and 15. The cloned exons were flanked by β-globin, exons E1 and E3 (Fig. 3A). Transfection of the plasmid constructs into UMSCC12 cells and RT-PCR analysis revealed that there is a correctly spliced product (upper band) in cells transfected with exon 10 and 15 pDup constructs. In the case of pDup exon 11 construct, an additional smaller band was seen that lacked exon 11 on sequencing. A transcript-specific real-time PCR strategy similar to the above described E-cadherin wild-type and aberrant transcripts (Fig. 2) was developed to quantify improperly spliced E1–E3 and the correctly spliced E1–exon 11–E3 transcripts in the mini-
gene construct (Fig. 3C). Tert-kert cells and head and neck cell lines were transiently transfected with the exon 11 minigene construct and 48 hours later, a real-time RT-PCR analysis was done. Figure 3D shows head and neck cell lines with a 2- to 3-fold increase in aberrant splicing versus nontransformed tert keratinocytes, providing additional evidence that the E-cadherin exon 11 is improperly spliced in head and neck cell lines.

Role of splicing factors in aberrant splicing

Because we did not identify mutations in exon 11 and the intronic region in 2 head and neck cell lines, we analyzed splicing factors as potential modulators of exon 11 skipping. We analyzed the exon 11 sequence with the exonic splicing enhancer finder software program (33) to determine the putative binding sites of known splicing factors and observed binding sites for the SFRS1, 2, 5, and 6 splice factors (34, 35) in exon 11 and its neighboring intronic region (~225 to +175 bp; Fig. 4). The expression of these splicing factors in head and neck lines relative to
tart-kert is shown in Fig. 4B. A consistent finding was the upregulation of a SFRS2 splicing factor, which formed the rationale for further analysis. Similar analysis in Fig. 4C shows expression of splicing factors in primary head and neck tumors relative to the matched normal tissue. In 5 of 7 pairs analyzed, SFRS2 was also upregulated in tumor tissues as compared with the other splicing factors, which corroborates the head and neck cell line data.

This was further analyzed with the minigene exon 11 construct (Fig. 3A), which was cotransfected with siRNA (10 nmol/L) targeting the splice factor SFRS2 (12) in UMSCC12 and UMSCC22b cells. A scrambled siRNA control transfected along with the minigene construct was used as the control to determine the relative ratio of the correctly spliced E1–11–E3 transcript. Western blot analysis (Fig. 5A) confirmed successful knockdown of SFRS2 in UMSCC12 and UMSCC22b cells. Figure 5B shows the data from 3 transfections (mean ± SD, n = 3). C, E-cadherin expression by real-time PCR analysis in 2 cell lines transfected with varying amounts of SFRS2 siRNA cells, the aberrant transcript decreased from 25% ± 6% to 8% ± 3.4% (mean ± SD, 2-tailed P = 0.013). Both cell lines showed that inactivation of SFRS2 splicing factor results in an increase in the correctly spliced exon 11 minigene transcript and decrease in the aberrant transcript. To determine the effect of siRNA knockdown on the endogenous E-cadherin gene splicing, these 2 cell lines were transiently transfected with varying amounts of siRNA. The increase in UMSCC12 cells was marginal, whereas in UMSCC22b cells, there was a 2.5-fold increase in wild-type transcripts.
Methylation status and splicing

Promoter methylation of the E-cadherin gene downregulates its expression (22, 23, 28) that can be reversed by hypomethylating agents, such as azacitidine, which are also being used in the clinical setting as well (reviewed in ref. 36). Also, as transcription and splicing occur simultaneously in the cell and inclusion of certain exons is dependent upon the transcriptional state of the gene, we investigated whether changes in E-cadherin transcription by hypomethylation could affect exon 11 splicing. Two head and neck cancer cell lines, UMSCC1 and 22b, were treated with 5-aza-deoxyctydine (5 µmol/L for 4 days) and analyzed for DNA hypomethylation, E-cadherin expression, and quantification of the 2 transcripts. Figure 6A shows the methylation-specific PCR conducted on bisulfite-treated DNA from untreated and azacitidine-treated cells (28). As expected, azacitidine treatment resulted in the amplification of a band with primers specific for the nonmethylated DNA, which is not seen in DNA from untreated cells. Identically, treated cells also showed increase in E-cadherin expression by Western blot analysis in the 2 cell lines (Fig. 6B). Figures 6C and D describe the RNA transcript analysis with data. UMSCC1 and UMSCC22b cells upon azacitidine treatment showed an increase in the wild-type E-cadherin transcript (16- to 28-fold) with a corresponding decrease in the exon 11–skipped transcript decreases relative to the wild-type transcript (5- to 30-fold decrease). As the overall transcription increases secondary to promoter hypomethylation, it is expected that both the transcripts would increase and potentially increase to the same extent. However the results pointed toward a preferential increase in the wild-type transcript in the azacitidine-treated cells. The data showed that the exon 11–skipped transcript can be clearly modulated by the hypomethylation process and is not a random phenomenon.

Discussion

We initiated this study to determine whether a previously identified E-cadherin RNA splicing abnormality that results in loss of E-cadherin expression in chronic lymphocytic leukemia cells (21) could also be found in solid tumors. Because the majority of human cancers are epithelial in origin and E-cadherin has a well-documented role in cell–cell adhesion and junctional complexes, we thought it important to see whether exon 11 skipping could play a role in loss of expression. The results show an increase in exon 11–skipped transcript in several solid tumor types along with decreased total E-cadherin expression. Because the frequency of exon 11 skipping was highest in head and neck tumors, we focused on this tumor for subsequent studies. Even though the exon 11–skipped transcript can be amplified from normal control tissues, it is more abundantly expressed in head and neck tumors and cell lines that have a lower expression of E-cadherin.

The differential splicing or changes in alternative splicing patterns of exon 11 between normal and tumor cells could be secondary to differential expression of splicing factors. We chose to study the SFRS2 splicing factor because it has a putative binding site in the E-cadherin exon 11 and is overexpressed in head and neck cell lines and primary tumor tissues as compared with the other splicing factors (Fig. 4, Fig. 5). This splicing factor is reported to have a role in the alternative splicing of the tumor suppressor gene KLF6 (12). To determine whether the overexpression of this factor plays a role in aberrant splicing, it was knocked down in 2 cell lines and changes in minigene construct splicing pattern were observed (Fig. 5) along with a dose-dependent increase in wild-type E-cadherin expression when different amounts of SFRS2 siRNA were used. The ability of SFRS2 siRNA to significantly enhance exon 11–incorporated transcripts suggests the upregulation of SFRS2 in head and neck cell lines may be involved in aberrant exon 11 splicing. In addition, the ability of knockdown to significantly increase expression of the wild-type transcript in the UMSCC22b cell line suggests that the enhanced aberrant splicing plays a role in loss-of-expression of this tumor suppressor gene rather than just representing an epi-phenomenon. However, it is certainly possible that...
additional splicing factors not studied also play a role in the observed aberrant splicing.

Our studies with azacytidine address 2 related processes, gene transcription and splicing. Our data show that azacytidine treatment results in hypomethylation of the E-cadherin promoter and an increase in transcription (Fig. 6), along with changes in the splicing pattern of the cells with a preferential increase in the wild-type transcript. Conversely, methylation of this gene that is frequently observed in human malignancies can potentially decrease E-cadherin expression with both transcriptional repression and an increase in exon 11 missplicing. There are 2 possible explanations for methylation status to result in splicing changes. First, hypomethylation changes the nature of the transcriptional complex formed at the promoter that then recruits additional factors that have a dual role as transcriptional factors and also affect splicing of exons (37–40). In the fibronectin gene model, the C-terminal domain is required for interaction with inhibitory splicing factors such as SRp20 to promote exon skipping (17). Second, methylation could influence the lysine residues of the histones (reviewed in 14, 18, 36, 41) and the resulting chromatin changes increase exon 11 missplicing, which is reversed by azacytidine treatment. Studies are ongoing to further elucidate the relative contribution of these 2 processes in exon 11 skipping.

In summary, head and neck cancer cell lines, primary tissues, and a number of other malignancies harbor an aberrantly spliced E-cadherin transcript that is present in much larger amounts compared with the normal cells. As expression of E-cadherin gene is frequently lost in tumor cells, missplicing of this exon is an interesting model to study the potential role of genetic and epigenetic events that affect splicing in cancer cells. It is also plausible that transcription factors involved in epithelial to mesenchymal transformation, for example, snail and zeb (42, 43), change the splicing milieu of the cells as they downregulate E-cadherin expression. The findings have a potential for clinical implications as epigenetic events can be reversed for reexpressing this tumor suppressor gene.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

We thank Dr. Douglas Black, HHMI UCLA, for useful suggestions and discussions and Dr. Eri Servatsan and Gwen Jordaen for help with cell culture work. Microarray experiments were done at the UCLA Microarray core facilities.

Grant Support

S. Sharma was a recipient of a grant from Flight Attendants Medical Research Institute (FAMRI), ASCO Foundation Young Investigator Award, and a VA Merit award. A. Lichtenstein was supported by grant CA 96920 and CA111448, and research funds from the Veteran’s Administration. X. Zhou was supported by K22DE01847, RO1CA139976, RO3CA135992, and a grant from Prevent Cancer Foundation. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received April 5, 2011; revised June 10, 2011; accepted July 7, 2011; published OnlineFirst July 15, 2011.

References

Molecular Cancer Therapeutics

Exon 11 Skipping of E-Cadherin RNA Downregulates Its Expression in Head and Neck Cancer Cells

Sanjai Sharma, Wei Liao, Xiaofeng Zhou, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/1535-7163.MCT-11-0248

Supplementary Material
Access the most recent supplemental material at:
http://mct.aacrjournals.org/content/suppl/2011/07/13/1535-7163.MCT-11-0248.DC1

Cited articles
This article cites 43 articles, 11 of which you can access for free at:
http://mct.aacrjournals.org/content/10/9/1751.full#ref-list-1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.